Status:

COMPLETED

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Lead Sponsor:

Boehringer Ingelheim

Collaborating Sponsors:

Eli Lilly and Company

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of this trial is to investigate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combina...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Healthy male and female subjects
  • age of 18 to 55 years
  • body mass index (BMI) of 18.5 to 29.9 kg/m2
  • additional inclusion criteria may apply
  • Exclusion criteria:
  • Any finding in the medical examination (including BP, PR or ECG) deviating from normal and judged as clinically relevant by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg or diastolic blood pressure outside the range of 50 to 90 mmHg or pulse rate outside the range of 45 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication
  • Diseases of the central nervous system (including but not limited to any kind of seizures and stroke), and other relevant neurological disorders or psychiatric disorders
  • additional exclusion criteria may apply

Exclusion

    Key Trial Info

    Start Date :

    November 1 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2014

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT02266472

    Start Date

    November 1 2014

    End Date

    December 1 2014

    Last Update

    March 9 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Boehringer Ingelheim Investigational Site

    Ingelheim, Germany